Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018107072) BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/107072 International Application No.: PCT/US2017/065385
Publication Date: 14.06.2018 International Filing Date: 08.12.2017
IPC:
C07D 207/12 (2006.01) ,A61K 31/40 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
207
Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
04
having no double bonds between ring members or between ring members and non-ring members
10
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
12
Oxygen or sulfur atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Applicants:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 210 W. 7th Street Austin, TX 78701, US
Inventors:
SOTH, Michael, J.; US
LIU, Gang; US
LE, Kang; US
CROSS, Jason; US
JONES, Philip; US
Agent:
DESPER, John; US
Priority Data:
62/431,50408.12.2016US
Title (EN) BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE
(FR) INHIBITEURS BICYCLO[1.1.1]PENTANE DE LA DOUBLE FERMETURE À GLISSIÈRE DE LEUCINE KINASE (DLK) DESTINÉS AU TRAITEMENT DE MALADIE
Abstract:
(EN) Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy -induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
(FR) La présente invention concerne des composés qui inhibent l’activité de la kinase de la double fermeture à glissière de leucine kinase (DLK) (MAP3K12), des compositions pharmaceutiques, et des procédés de traitement de maladies à médiation par la DLK, telles que des maladies neurologiques qui résultent d’une lésion traumatique au système nerveux central et aux neurones du système nerveux périphérique (par exemple, accident vasculaire cérébral, lésion traumatique du cerveau, lésion de la moelle épinière), ou qui résultent d’un état de neurodégénérescence chronique (par exemple, maladie d’Alzheimer, démence fronto-temporale, maladie de Parkinson, maladie de Huntington, sclérose latérale amyotrophique, ataxie spinocérébelleuse, paralysie supranucléaire progressive, maladie à corps de Lewy, maladie de Kennedy, et autres états apparentés), de neuropathies résultant de détérioration neurologique (neuropathie périphérique induite par la chimiothérapie, neuropathie diabétique, et états apparentés) et de troubles cognitifs causés par l’intervention pharmacologique (par exemple la perturbation cognitive post-chimiothérapie, également connu par brouillard de la chimiothérapie).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)